Pharmaceutical Residual Azide Testing

PHARMACEUTICAL PROCESS SUPPORT

When a Process Question Cannot Wait for Final Analysis



A process-development or quality team may know that azide chemistry was used but not yet know which in-process or cleaning-development samples deserve priority while validated laboratory work continues. The immediate need is rapid, controlled feedback that can guide an investigation without becoming the final quality decision.

That need became highly visible when Health Canada documented 2021 recalls involving azido impurities in sartan medicines. Those events involved trace organic azido impurities and laboratory methods; they do not establish that a ChemSee card is suitable for AZBT, AZBC or another trace impurity. ChemSee instead reviews compatible process samples where higher-level inorganic azide screening may assist development, troubleshooting, cleaning work or sample triage.

For an approved sample, ChemSee determines whether AZD-N2 or AZD-P2 can provide a useful qualitative screen while the organization’s validated and confirmatory methods remain in control.


METHOD GOVERNANCE

Screening Is One Layer

A rapid qualitative screen can support a defined internal workflow, but the user remains responsible for qualification or validation, controls, records, specifications and confirmatory analysis appropriate to the process and product.


Product Selection

Card Reviewed sample condition Product response threshold Role
AZD-N2 Neutral-to-mildly-acidic solutions, pH 5–8; biological and pharmaceutical materials and other approved samples Azides above 50 ppm Qualitative color-change screen
AZD-P2 Basic solutions, pH 8–14 Azides above 100 ppm Qualitative screen with pretreatment pouch intended to avoid hydrazoic-acid exposure

Under the documented configurations, AZD-N2 provides a result in approximately 1–2 minutes and AZD-P2 in 1–4 minutes including preparation. A prescribed positive produces a dark-brown to black response in the indicator zone. Neither configuration requires an electronic reader; both are stored below 75°F (24°C) and have a shelf life of at least two years under current instructions.

Product thresholds are not automatically equivalent to a process specification, reporting limit or acceptable carryover criterion.


Potentially Appropriate Questions



DEVELOPMENT

Process Troubleshooting

Does an applicable qualitative response appear in a technically reviewed in-process sample while the formal investigation and analytical plan continue?


CLEANING

Cleaning-Development Support

Can a reviewed screen contribute rapid feedback during development work before a validated verification method is established?


TRIAGE

Sample Triage

Can selected samples be prioritized for confirmatory analysis without treating the card as the final quality decision?



Application Information ChemSee Needs

  • Drug-substance or process stage and sample identity
  • Expected azide chemistry and approximate level, if known
  • pH, matrix composition, water content and color
  • Potential interfering or reactive components
  • Sample preparation and containment constraints
  • Proposed specification or decision point
  • Required documentation, controls and confirmatory method

A Controlled Development Workflow

  1. Define intended use. State whether the card is being considered for development, troubleshooting, triage or another internal purpose.
  2. Assess the matrix. Review pH, composition, color, preparation and potential interferences.
  3. Select and challenge the card. Choose AZD-N2 or AZD-P2 for the reviewed conditions and establish appropriate controls under the user’s quality system.
  4. Document observations. Record the sample, preparation, lot, conditions, prescribed response and any deviations.
  5. Confirm and govern the decision. Use appropriate confirmatory analysis and complete the user’s qualification or validation before relying on the method for a controlled quality decision.

Pharmaceutical Method Limitations

Neither card is automatically a validated release, cleaning-verification, stability, compendial or regulatory method. Suitability for a drug substance, product, cleaning process or manufacturing decision requires application review and the user’s own qualification or validation, representative sampling, controls, acceptance criteria, records and confirmatory analysis. A negative response does not establish that a sample is free of azide or meets a specification.

Describe the azide chemistry, process stage, matrix, pH and intended decision. ChemSee will assess whether a rapid qualitative screen can shorten the investigation without replacing the validated method.